Literature DB >> 23841880

Meta-analysis: Lactobacillus GG for treating acute gastroenteritis in children--updated analysis of randomised controlled trials.

H Szajewska1, A Skórka, M Ruszczyński, D Gieruszczak-Białek.   

Abstract

BACKGROUND: The efficacy of each probiotic should be evaluated separately. Previously, we have shown that Lactobacillus GG (LGG) is effective in treating acute gastroenteritis (AGE) in children. AIM: To update our 2007 meta-analysis on the effectiveness of LGG in treating AGE in children.
METHODS: The Cochrane Library, MEDLINE and EMBASE databases were searched from August 2006 (end date of last search) to May 2013, with no language restrictions, for randomised controlled trials (RCTs) and meta-analyses.
RESULTS: Fifteen RCTs (2963 participants) met the inclusion criteria in this updated meta-analysis. Combined data from 11 RCTs (n = 2444) showed that LGG significantly reduced the duration of diarrhoea compared with placebo or no treatment (mean difference, MD -1.05 days, 95% CI -1.7 to -0.4). LGG was more effective when used at a daily dose ≥10¹⁰ CFU (eight RCTs, n = 1488, MD -1.11 days, 95% CI -1.91 to -0.31) than when used at a daily dose <10¹⁰ CFU (three RCTs, n = 956, MD -0.9 day, 95% CI -2.5 to 0.69). LGG was effective in children treated in Europe (five RCTs, n = 744, MD -1.27 days, 95% CI -2.04 to -0.49); in the non-European setting, the difference between the LGG group and the control group was of a borderline statistical significance (six RCTs, n = 1700, MD -0.87, 95% CI -1.81 to 0.08).
CONCLUSIONS: Lactobacillus GG reduces the duration of diarrhoea. A subset of patients that is more likely to benefit includes subjects treated with a high daily dose of LGG (≥10¹⁰ CFU/day) who are either in-patients or out-patients from geographical Europe. Given the methodological limitations of many of the included trials, the evidence should be viewed with caution.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2013        PMID: 23841880     DOI: 10.1111/apt.12403

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  38 in total

Review 1.  Probiotics in the next-generation sequencing era.

Authors:  Jotham Suez; Niv Zmora; Eran Elinav
Journal:  Gut Microbes       Date:  2019-04-05

Review 2.  Modulation of microbiota as treatment for intestinal inflammatory disorders: An uptodate.

Authors:  Antonella Gallo; Giovanna Passaro; Antonio Gasbarrini; Raffaele Landolfi; Massimo Montalto
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

3.  Gelatin Tannate for Acute Childhood Gastroenteritis: A Randomized, Single-Blind Controlled Trial.

Authors:  Maurizio Mennini; Carlo Tolone; Antonella Frassanito; Fabio Midulla; Salvatore Cucchiara; Marina Aloi
Journal:  Paediatr Drugs       Date:  2017-04       Impact factor: 3.022

4.  Lactobacillus rhamnosus GG versus Placebo for Acute Gastroenteritis in Children.

Authors:  David Schnadower; Phillip I Tarr; T Charles Casper; Marc H Gorelick; J Michael Dean; Karen J O'Connell; Prashant Mahajan; Adam C Levine; Seema R Bhatt; Cindy G Roskind; Elizabeth C Powell; Alexander J Rogers; Cheryl Vance; Robert E Sapien; Cody S Olsen; Melissa Metheney; Viani P Dickey; Carla Hall-Moore; Stephen B Freedman
Journal:  N Engl J Med       Date:  2018-11-22       Impact factor: 91.245

5.  Association between Age, Weight, and Dose and Clinical Response to Probiotics in Children with Acute Gastroenteritis.

Authors:  David Schnadower; Robert E Sapien; T Charles Casper; Cheryl Vance; Phillip I Tarr; Karen J O'Connell; Adam C Levine; Cindy G Roskind; Alexander J Rogers; Seema R Bhatt; Prashant Mahajan; Elizabeth C Powell; Cody S Olsen; Marc H Gorelick; J Michael Dean; Stephen B Freedman
Journal:  J Nutr       Date:  2021-01-04       Impact factor: 4.798

6.  Ehealth: low FODMAP diet vs Lactobacillus rhamnosus GG in irritable bowel syndrome.

Authors:  Natalia Pedersen; Nynne Nyboe Andersen; Zsuzsanna Végh; Lisbeth Jensen; Dorit Vedel Ankersen; Maria Felding; Mette Hestetun Simonsen; Johan Burisch; Pia Munkholm
Journal:  World J Gastroenterol       Date:  2014-11-21       Impact factor: 5.742

7.  Piliation of Lactobacillus rhamnosus GG promotes adhesion, phagocytosis, and cytokine modulation in macrophages.

Authors:  Cynthia E Vargas García; Mariya Petrova; Ingmar J J Claes; Ilke De Boeck; Tine L A Verhoeven; Ellen Dilissen; Ingemar von Ossowski; Airi Palva; Dominique M Bullens; Jos Vanderleyden; Sarah Lebeer
Journal:  Appl Environ Microbiol       Date:  2015-01-09       Impact factor: 4.792

Review 8.  A gastrointestinal anti-infectious biotherapeutic agent: the heat-treated Lactobacillus LB.

Authors:  Vanessa Liévin-Le Moal
Journal:  Therap Adv Gastroenterol       Date:  2016-01       Impact factor: 4.409

9.  Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis.

Authors:  J S Bajaj; D M Heuman; P B Hylemon; A J Sanyal; P Puri; R K Sterling; V Luketic; R T Stravitz; M S Siddiqui; M Fuchs; L R Thacker; J B Wade; K Daita; S Sistrun; M B White; N A Noble; C Thorpe; G Kakiyama; W M Pandak; M Sikaroodi; P M Gillevet
Journal:  Aliment Pharmacol Ther       Date:  2014-03-16       Impact factor: 8.171

10.  Probiotics in Disease Prevention and Treatment.

Authors:  Yuying Liu; Dat Q Tran; J Marc Rhoads
Journal:  J Clin Pharmacol       Date:  2018-10       Impact factor: 3.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.